Unlocking Insights: The Link Between Systemic Inflammation Response Index and Short-Term Al

Unlocking Insights: The Link Between Systemic Inflammation Response Index and Short-Term Al

November 18, 2024 Catherine Williams - Chief Editor Health

Introduction to Cirrhosis

Cirrhosis is a chronic liver disease caused by ongoing inflammation and fiber formation, leading to significant liver damage. It ranks as the 11th leading cause of death globally and is the third most common cause of death for people aged 45 to 64. Approximately 2 million people die from cirrhosis each year, making it a major health issue. Decompensated liver cirrhosis (DLC) marks a critical and severe stage of the disease, characterized by significant liver function decline and life-threatening complications. The short-term death rate in patients with DLC can reach up to 15%. Early detection and timely treatment are crucial for improving outcomes.

Study Subjects

This study involved 926 patients with DLC meeting specific inclusion criteria. Key demographic data included a mean patient age of 64 years, with 45% female and 55% male. Chronic hepatitis B virus (HBV) infection was the primary cause of cirrhosis in 65.7% of cases. Complications noted included ascites (74.6%), esophageal variceal bleeding (19.3%), hepatic encephalopathy (6.1%), and hepatorenal syndrome (2.2%). The mortality rates at 3 and 6 months were 8.8% and 11.6%, respectively.

Data Collection and Methods

Data was collected at admission, including age, gender, cause of cirrhosis, and complications such as ascites, variceal bleeding, and hepatic encephalopathy. Blood tests provided data for the systemic inflammation response index (SIRI) calculated using specific formulas. Statistical analysis included t-tests, chi-square tests, and receiver operating characteristic (ROC) curves to assess the predictive ability of SIRI for all-cause mortality.

Findings

At 3 and 6 months, ROC analysis showed SIRI AUC values of 0.841 and 0.807, respectively. Patients were divided into high and low SIRI groups based on the Youden index. High SIRI was associated with higher neutrophil, monocyte, total bilirubin, and prothrombin time levels, alongside decreased albumin. Mortality rates were also higher in the high SIRI group. In the validation cohort, AUC values were 0.773 and 0.747, indicating SIRI’s promising predictive capabilities.

Discussion

The study established that elevated SIRI levels are independently linked to increased mortality risk in DLC patients. Inflammation significantly impacts DLC prognosis, exacerbating complications and reducing survival rates. The relationship between inflammatory cell profiles and patient outcomes highlights the importance of monitoring systemic inflammation for prognosis.

The study confirmed SIRI as a viable biomarker for predicting short-term mortality in DLC. Its non-invasive and cost-effective nature makes it practical for clinical use, allowing earlier intervention and resource allocation for high-risk patients.

Conclusion

This research identified SIRI as an important biomarker for predicting short-term mortality in patients with DLC. Systemic inflammation’s role in liver cirrhosis progression suggests that SIRI could improve patient management and outcomes. Recognizing high-risk individuals enables better treatment strategies and resource utilization.

Ethics Approval

The study followed the Declaration of Helsinki, receiving ethics approval from relevant committees. Informed consent was waived according to legal and institutional guidelines.

Author Contributions and Funding

The authors declare no conflict of interest, and there was no external funding for this research.